Please login to the form below
MeiraGTx
This page shows the latest MeiraGTx news and features for those working in and with pharma, biotech and healthcare.
J&J bolsters gene therapy unit with $100m MeiraGTx deal
Licenses two inherited retinal disorder candidates. Johnson &Johnson has made its biggest move into gene therapy, signing a $100m deal with UK-headquartered biotech MeiraGTx for rights to two genetic eye ... MeiraGTx is also working on gene therapies for
Latest news
-
Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
MeiraGTx is developing therapies for diseases of the eye, salivary glands and central nervous system. ... Funds raised from the IPO will enable MeiraGTx to progress its product candidates to treat inherited rare eye diseases, xerostomia (‘dry mouth’)
Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Digital account director
-
Competitive
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome
- Migraine-friendly colours for the home
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
